Citations (5)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
C. Menigoz, S. Dirou, A. Chambellan, D. Hassoun, A. Moui, A. Magnan & F. X. Blanc. (2023) Use of FeNO to predict anti-IL-5 and IL-5R biologics efficacy in a real-world cohort of adults with severe eosinophilic asthma. Journal of Asthma 60:6, pages 1162-1170.
Read now
Read now
Articles from other publishers (4)
Fred Fyles, Amy Nuttall, Hannah Joplin & Hassan Burhan. (2023) Long-Term Real-World Outcomes of Mepolizumab and Benralizumab Among Biologic-Naive Patients With Severe Eosinophilic Asthma: Experience of 3 Years’ Therapy. The Journal of Allergy and Clinical Immunology: In Practice 11:9, pages 2715-2723.
Crossref
Crossref
Tommaso Pianigiani, Lorenzo Alderighi, Martina Meocci, Maddalena Messina, Beatrice Perea, Simona Luzzi, Laura Bergantini, Miriana D’Alessandro, Rosa Metella Refini, Elena Bargagli & Paolo Cameli. (2023) Exploring the Interaction between Fractional Exhaled Nitric Oxide and Biologic Treatment in Severe Asthma: A Systematic Review. Antioxidants 12:2, pages 400.
Crossref
Crossref
. (2022) Benralizumab/mepolizumab. Reactions Weekly 1937:1, pages 117-117.
Crossref
Crossref
Zhuya Yang, Xiaohong Li, Rongbing Fu, Min Hu, Yijie Wei, Xuhong Hu, Wenhong Tan, Xiaoyun Tong & Feng Huang. (2022) Therapeutic Effect of Renifolin F on Airway Allergy in an Ovalbumin-Induced Asthma Mouse Model In Vivo. Molecules 27:12, pages 3789.
Crossref
Crossref